EA201490638A1 - КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ - Google Patents

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ

Info

Publication number
EA201490638A1
EA201490638A1 EA201490638A EA201490638A EA201490638A1 EA 201490638 A1 EA201490638 A1 EA 201490638A1 EA 201490638 A EA201490638 A EA 201490638A EA 201490638 A EA201490638 A EA 201490638A EA 201490638 A1 EA201490638 A1 EA 201490638A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
treating cancer
compositions
methods
signal path
Prior art date
Application number
EA201490638A
Other languages
English (en)
Inventor
Карлос ГАРСИЯ-ЭЧЕВЕРРИЯ
Лоик Венсан
Анжела Вирон-Оддо
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851503&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи filed Critical Санофи
Publication of EA201490638A1 publication Critical patent/EA201490638A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к композициям, содержащим по меньшей мере один ингибитор сигнального пути MAPK, включая MEK и RAF ингибиторы, и по меньшей мере один ингибитор PI3Kβ, a также к их применению для лечения рака.
EA201490638A 2011-09-16 2012-09-14 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ EA201490638A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306172A EP2570127A1 (en) 2011-09-16 2011-09-16 Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
PCT/EP2012/068072 WO2013037943A1 (en) 2011-09-16 2012-09-14 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors

Publications (1)

Publication Number Publication Date
EA201490638A1 true EA201490638A1 (ru) 2014-08-29

Family

ID=46851503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490638A EA201490638A1 (ru) 2011-09-16 2012-09-14 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ

Country Status (25)

Country Link
US (1) US20140275078A1 (ru)
EP (2) EP2570127A1 (ru)
JP (1) JP2014530181A (ru)
KR (1) KR20140062143A (ru)
CN (1) CN103889418A (ru)
AR (1) AR087902A1 (ru)
AU (1) AU2012307309A1 (ru)
BR (1) BR112014005839A2 (ru)
CA (1) CA2847091A1 (ru)
CL (1) CL2014000606A1 (ru)
CO (1) CO6910192A2 (ru)
CR (1) CR20140102A (ru)
DO (1) DOP2014000046A (ru)
EA (1) EA201490638A1 (ru)
EC (1) ECSP14013244A (ru)
GT (1) GT201400038A (ru)
IL (1) IL231212A0 (ru)
MA (1) MA35615B1 (ru)
MX (1) MX2014003223A (ru)
NI (1) NI201400020A (ru)
PE (1) PE20141035A1 (ru)
SG (1) SG11201400380XA (ru)
TN (1) TN2014000086A1 (ru)
UY (1) UY34341A (ru)
WO (1) WO2013037943A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209073A (zh) 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
US20160030440A1 (en) * 2013-04-05 2016-02-04 Sanofi Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
US10111897B2 (en) 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
WO2015161230A1 (en) * 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR101950094B1 (ko) 2017-07-28 2019-02-19 이성재 보릿대 공예품 제작방법
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MY153042A (en) 2009-07-02 2014-12-31 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
FR2951169B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Also Published As

Publication number Publication date
WO2013037943A1 (en) 2013-03-21
US20140275078A1 (en) 2014-09-18
GT201400038A (es) 2014-12-16
NI201400020A (es) 2014-04-23
DOP2014000046A (es) 2014-07-15
CO6910192A2 (es) 2014-03-31
UY34341A (es) 2013-04-05
WO2013037943A8 (en) 2013-07-18
BR112014005839A2 (pt) 2017-03-28
IL231212A0 (en) 2014-04-30
TN2014000086A1 (en) 2015-07-01
EP2755653A1 (en) 2014-07-23
JP2014530181A (ja) 2014-11-17
CA2847091A1 (en) 2013-03-21
SG11201400380XA (en) 2014-04-28
AU2012307309A1 (en) 2014-04-03
CL2014000606A1 (es) 2014-11-07
CN103889418A (zh) 2014-06-25
MA35615B1 (fr) 2014-11-01
PE20141035A1 (es) 2014-09-04
AR087902A1 (es) 2014-04-23
CR20140102A (es) 2014-05-07
MX2014003223A (es) 2014-06-05
ECSP14013244A (es) 2014-07-31
EP2570127A1 (en) 2013-03-20
KR20140062143A (ko) 2014-05-22

Similar Documents

Publication Publication Date Title
EA201490638A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ
MX2016006316A (es) Inhibidores de mtor para potenciar la respuesta inmunitaria.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201692104A1 (ru) Ингибиторы асс и их применения
EA201691461A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
ECSP14030779A (es) Inhibidores del nampt
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA201490688A1 (ru) 2-тиопиримидиноны
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201690844A1 (ru) Ингибиторы gsk-3
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
EA201592108A1 (ru) Гетероциклические соединения в качестве ингибиторов сигнального пути hedgehog
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
EA201500752A1 (ru) Способ лечения заболеваний
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов